# Compare Selank and DSIP — Peptivio Peptides

> A side-by-side comparison of Selank and DSIP — two Cognitive & Nootropic research peptides — across peptide class, mechanism, evidence maturity, regulatory status, and key cautions.

Two neuroactive research peptides from the mood-and-stress space — one with a partially characterized mechanism and limited clinical data, one with a genuinely unresolved mechanism and inconsistently replicated effects.

## The short version

This page lines up [Selank](/selank) and [DSIP](/dsip) on the dimensions that matter most when reading research peptides: what kind of molecule each one is, what it is proposed to do and by what mechanism, how strong and consistent the evidence is, its regulatory standing, and its most important caution. The headline is direct. Both are studied in the mood, stress, and sleep space, but they are at very different stages of scientific understanding: Selank has a reasonably characterized (if still incompletely established) mechanism and limited Russian clinical data; DSIP has no identified receptor or gene after forty-plus years of research, and a large share of users report no effect at all. Neither is an approved medicine. Neither is presented here with a human dose.

## The comparison matrix

| Dimension | Selank | DSIP |
| --- | --- | --- |
| **Class** | Synthetic heptapeptide, tuftsin analogue (TP-7) | Endogenous nonapeptide (WAGGDASGE), INN: emideltide |
| **What it is studied for** | Anxiety, stress resilience, nootropic / BDNF effects | Sleep-onset, slow-wave (delta) sleep, stress-hormone modulation |
| **Proposed mechanism** | Positive allosteric modulation of GABA receptors; enkephalinase inhibition; BDNF expression [1][3][7] | **Genuinely unknown** — no receptor, gene, or precursor identified [9] |
| **Human evidence** | Small Russian clinical trials in anxiety disorders with active comparator [6]; immunomodulation study [5] | Small 1981 insomnia pilot (n=6) [12]; 1989 ACTH modulation study [11] |
| **Evidence quality** | Preclinical-heavy; single-region; not independently replicated in West | Inconsistently replicated; 2006 review calls sleep evidence "extremely poorly documented and still weak" [9] |
| **Regulatory status** | Not approved (FDA/EMA); registered only in Russia as anxiolytic; research chemical elsewhere | Not approved anywhere; sold research-chemical only |
| **WADA status** | Not specifically listed; CNS peptides not a standard prohibited class | Not specifically listed; WADA S0 catch-all may apply as a non-approved substance |
| **Community response rate** | Most responders notice something; non-response is a minority | Estimated ~50% non-response; "did nothing" is a large community voice |
| **Key caution** | Single-region evidence; unknown long-term safety; interaction unknowns across GABA/opioid/immune systems [6] | Mechanism unknown; effects inconsistent; large non-response; unknown interactions [9] |

## Mechanism: a meaningful divergence

The most important difference between these two compounds is what is known about how they work. Selank has a plausible, experimentally grounded mechanism: positive allosteric modulation of GABA receptors demonstrated in binding assays, gene-expression changes in the GABAergic pathway measured in rat frontal cortex, enkephalinase inhibition shown in human plasma in vitro, and synergy with diazepam in a rat stress model [1][2][3][7]. Each of those links is a building block in a coherent story, even if that story has not been assembled into a complete human pharmacology.

DSIP, by contrast, has no identified receptor, no identified gene, and no established precursor protein despite forty-plus years of study [9]. What it has is an original observation (infused into rabbit brains, it appeared to promote slow-wave sleep) and a collection of associated findings that have not coalesced into a mechanism. The 2024 mouse study with a modified fusion peptide showed interesting effects — but the unmodified native peptide was less effective in the same experiment [8], which is not reassuring about the molecule currently sold as a research chemical.

## Regulatory standing and research context

Neither compound is approved by the FDA or EMA for any indication. Selank's closest thing to regulatory recognition is its registration as an anxiolytic in Russia, where the human clinical studies were conducted; outside that context it is a research chemical [6]. DSIP has an INN (emideltide) but no approved emideltide product has ever reached market anywhere.

Neither compound is specifically named on the current WADA Prohibited List, though WADA's broad S0 "non-approved substances" category can encompass unapproved pharmacological agents, and athletic-research contexts should verify the current list before drawing any conclusions. Both should be treated with the caution appropriate to unapproved research chemicals with limited or contested human safety data.

## What the community actually reports

These are **anecdotal reports, not clinical evidence**, but they are an honest part of the picture.

For Selank, the most consistent community signal is calm without sedation — a reduction in background anxiety that feels qualitatively different from the heavy sedation of benzodiazepines or the emotional blunting of SSRIs. Responders commonly describe it as mental clarity plus reduced anxious noise. A meaningful minority report no effect or an effect so subtle they are unsure it was real, but non-response is not the dominant community voice for Selank the way it is for DSIP.

For DSIP, non-response is a major theme. A commonly repeated practitioner estimate puts the meaningful-response rate at roughly half of those who try it; forums are genuinely full of "did nothing" reports. Among responders, the most frequently described benefit is falling asleep more easily and waking without grogginess — but this is offset by adverse reports of unpredictable timing (sedation arriving the next day), next-day grogginess, and headache. The evidence is inconsistent enough that "DSIP is primarily interesting as a research target" is a defensible read of the community experience as well as the clinical literature.

---

An independent literature digest — curious, citation-grounded, and honest about what the research does and does not establish.